Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: CHINA

Sector: Biotechnology

Categories: @china   

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
Website: beigene.com


  • Good financial results growth rate 120.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (55.1%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 8.0% (LTM)
  • Share price is 42.6% higher than minimum and 24.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: BGNE
Share price, USD:  (0.0%)184.71
year average price 184.71  


year start price 184.71 2025-05-18

max close price 184.71 2025-05-18

min close price 184.71 2025-05-18

current price 184.71 2026-05-17
Common stocks: 82 691 313

Dividend Yield:  0.0%
EV / Sales: 2.5x
Margin (EBITDA LTM / Revenue): -7.7%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 15 274
Net Debt ($m): -3 017
EV (Enterprise Value): 12 257
EBITDA LTM (млн $): -381
Price to Book: 3.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-13businesswire.com

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

2025-04-29businesswire.com

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

2025-04-17businesswire.com

BeiGene to Announce First Quarter 2025 Financial Results on May 7

2025-04-03businesswire.com

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

2025-02-21zacks.com

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

2025-02-13businesswire.com

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

2024-12-27businesswire.com

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

2024-12-12businesswire.com

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

2024-12-09businesswire.com

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

2024-12-02businesswire.com

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-09-30 2024-08-07 2024-05-08 2023-11-09 2023-08-02 2023-05-04 2022-11-09
acceptedDate 2025-11-06 06:07:16 2025-08-06 06:05:46 2025-02-27 06:12:34 2024-09-30 00:00:00 2024-08-07 06:07:59 2024-05-08 06:09:45 2025-01-08 06:02:32 2023-11-09 16:14:07 2023-08-02 06:23:42 2023-05-04 07:17:19 2022-12-30 19:00:00 2022-11-09 07:12:00 2021-12-30 19:00:00 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 412M 1 315M 3 810M 1 002M 929M 752M 2 459M 781M 595M 448M 1 416M 388M 1 176M 309M
costOfRevenue 197M 165M 594M 170M 138M 125M 380M 96M 519M 82M 1 927M 503M 1 624M 1 366M
grossProfit 1 216M 1 151M 3 216M 831M 791M 627M 2 079M 685M 77M 366M -511M -115M -448M -1 057M
grossProfitRatio 0.861 0.875 0.83 0.851 0.834 0.877 0.129 0.817 -0.297
researchAndDevelopmentExpenses 524M 525M 1 953M 496M 454M 461M 1 779M 453M 423M 409M 1 641M 426M 1 459M 1 295M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 529M 538M 1 831M 455M 444M 427M 1 505M 364M 395M 328M 1 278M 323M 990M 600M
otherExpenses 0 0 0 0 0 2M 4M 337M -64M -408M 751 000 -426M 750 000 846 000
operatingExpenses 1 053M 1 063M 3 784M 951M 898M 888M 3 287M 818M 395M 329M 1 279M 323M 991M 601M
costAndExpenses 1 249M 1 227M 4 378M 1 122M 1 036M 1 013M 3 667M 914M 914M 737M 3 206M 826M 2 615M 1 967M
interestIncome 0 0 48M 11M 13M 16M 74M 27M 15M 16M 52M 0 14M 2M
interestExpense 0 0 0 0 0 0 0 18M 5M -34M 0 13M 29M 0
depreciationAndAmortization 37M 0 172M 71M 25M 25M 88M 22M 22M 20M 66M 16M 46M 32M
ebitda 184M 88M -396M -49M -82M -261M -1 120M -134M -296M -371M -1 723M -422M -1 392M -1 626M
ebitdaratio 0.131 0.067 -0.049 -0.088 -0.348 -0.171 -0.498 -0.829 -1.089
operatingIncome 163M 88M -568M -120M -107M -261M -1 208M -134M -319M -371M -1 790M -438M -1 439M -1 658M
operatingIncomeRatio 0.115 0.067 -0.12 -0.115 -0.348 -0.171 -0.535 -0.829 -1.131
totalOtherIncomeExpensesNet -16M 12M 35M 22M 1M 18M 382M 363M -64M 34M -171M -113M 147 000 39M
incomeBeforeTax 147M 100M -533M -98M -106M -243M -826M 229M -367M -337M -1 961M -551M -1 439M -1 618M
incomeBeforeTaxRatio 0.104 0.076 -0.098 -0.114 -0.324 0.294 -0.617 -0.752 -1.422
incomeTaxExpense 22M 5M 112M 23M 14M 8M 56M 14M 14M 11M 43M 6M 25M 18M
netIncome 125M 94M -645M -121M -120M -251M -882M 215M -381M -348M -2 004M -558M -1 413M -1 601M
netIncomeRatio 0.088 0.072 -0.121 -0.13 -0.334 0.276 -0.64 -0.778 -1.438
eps 14.69 11.31 -6.11 -1.15 -1.15 -1.85 -8.45 2.06 -3.64 -3.34 -19.37 -5.39 -15.21 -19.11
epsdiluted 14.17 10.92 -1.15 -1.15 -1.85 2.01 -3.64 -3.34 -5.39
weightedAverageShsOut 110M 108M 105M 106M 105M 136M 104M 105M 105M 104M 103M 103M 93M 83M
weightedAverageShsOutDil 115M 113M 105M 106M 105M 136M 104M 107M 105M 104M 103M 103M 93M 83M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2025-01-08 2022-12-31 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 48M 74M 52M -16M 2M
ebit -568M -1 208M -1 790M -1 439M -1 658M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -645M -882M -2 004M -1 458M -1 629M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -645M -882M -2 004M -1 458M -1 625M
epsDiluted -6.11 -8.45 -19.37 -15.21 -19.11

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-09-30 2024-08-07 2024-05-08 2023-11-09 2023-08-02 2023-05-04 2022-11-09
acceptedDate 2025-11-06 06:07:16 2025-08-06 06:05:46 2025-02-27 06:12:34 2024-09-30 00:00:00 2024-08-07 06:07:59 2024-05-08 06:09:45 2025-01-08 06:02:32 2023-11-09 16:14:07 2023-08-02 06:23:42 2023-05-04 07:17:19 2022-12-30 19:00:00 2022-11-09 07:12:00 2021-12-30 19:00:00 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 4 037M 2 756M 2 627M 2 702M 2 593M 2 762M 3 172M 3 067M 3 410M 3 539M 3 870M 4 197M 4 376M 1 382M
shortTermInvestments 0 0 0 0 0 43M 3M 107M 106M 294M 665M 872M 2 242M 3 269M
cashAndShortTermInvestments 4 037M 2 756M 2 627M 2 702M 2 593M 2 805M 3 174M 3 174M 3 516M 3 833M 4 540M 5 069M 6 625M 4 659M
netReceivables 863M 771M 709M 603M 588M 467M 396M 355M 338M 332M 199M 203M 500M 80M
inventory 532M 503M 495M 432M 443M 447M 416M 317M 321M 297M 282M 291M 243M 89M
otherCurrentAssets 233M 281M 25M 175M 215M 188M 167M 24M 41M 42M 134M 186M 129M 103M
totalCurrentAssets 5 664M 4 310M 3 992M 3 912M 3 839M 3 908M 4 203M 4 054M 4 401M 4 704M 4 713M 5 749M 7 614M 4 961M
propertyPlantEquipmentNet 1 768M 1 762M 1 657M 1 713M 1 620M 1 506M 1 419M 1 289M 1 145M 1 054M 846M 830M 687M 446M
goodwill 0 0 0 0 0 0 0 0 109 000 109 000 109 000 109 000 109 000 109 000
intangibleAssets 64M 65M 130M 54M 54M 55M 57M 54M 47M 40M 95M 41M 103M 54M
goodwillAndIntangibleAssets 64M 65M 130M 54M 54M 55M 57M 54M 47M 40M 95M 41M 103M 54M
longTermInvestments 0 0 129M 138M 140M 146M 90M 89M 96M 98M 92M 96M 101M 49M
taxAssets 0 0 0 0 0 -1 3M 30M 39M 0 0 0 110M 66M
otherNonCurrentAssets 136M 162M 13M 14M 60M 53M 36M 9M 2M 61M -186M 10M 31M 25M
totalNonCurrentAssets 1 968M 1 988M 1 929M 1 919M 1 873M 1 760M 1 602M 1 471M 1 327M 1 252M 846M 977M 1 032M 640M
otherAssets 0 0 0 0 0 1 0 0 0 0 820M 0 0 0
totalAssets 7 633M 6 298M 5 921M 5 831M 5 712M 5 668M 5 805M 5 525M 5 729M 5 957M 6 379M 6 726M 8 646M 5 601M
accountPayables 384M 361M 405M 308M 333M 357M 315M 342M 267M 241M 295M 252M 168M 232M
shortTermDebt 829M 826M 852M 882M 887M 846M 688M 352M 445M 306M 329M 466M 428M 335M
taxPayables 11M 6M 61M 49M 5M 27M 53M 43M 56M 62M 44M 49M 67M 35M
deferredRevenue 0 0 0 0 0 27M 0 300 000 159M 185M 256M 145M 408M 367M
otherCurrentLiabilities 1 145M 1 018M 360M 787M 713M 651M 196M 589M 535M 521M -110M 549M 353M 105M
totalCurrentLiabilities 2 368M 2 210M 2 215M 2 025M 1 939M 1 882M 1 810M 1 283M 1 405M 1 255M 1 018M 1 411M 1 600M 1 075M
longTermDebt 191M 200M 166M 220M 221M 199M 198M 228M 233M 239M 209M 245M 202M 184M
deferredRevenueNonCurrent 0 0 30M 32M 0 33M 300 000 34M 59M 75M 80M 188M 267M 49M
deferredTaxLiabilitiesNonCurrent 47M 44M 42M 16M 16M 16M 0 16M 16M 16M 16M 15M 14M 11M
otherNonCurrentLiabilities 897M 74M 91M 101M 171M 144M 238M 200M 217M 215M 734M -203M 277M 383M
totalNonCurrentLiabilities 1 135M 318M 374M 369M 407M 393M 458M 478M 525M 545M 978M 660M 803M 656M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 62M 50M 53M 18M 44M 49M 49M 57M 59M 61M 65M 43M
totalLiabilities 3 503M 2 528M 2 589M 2 395M 2 346M 2 274M 2 268M 1 762M 1 930M 1 799M 1 996M 2 071M 2 403M 1 732M
preferredStock 0 0 0 0 0 0 0 0 145M 0 0 0 0 0
commonStock 144 000 143 000 138 000 138 000 137 000 136 000 135 000 135 000 137 000 136 000 135 000 135 000 133 000 118 000
retainedEarnings -8 386M -8 511M -8 607M -8 455M -8 334M -8 213M -7 962M -7 594M -7 810M -7 429M -7 080M -6 635M -4 966M -3 553M
accumulatedOtherComprehensiveIncomeLoss -101M -114M -149M -84M -140M -132M -99M -145M -144M -59M -77M -162M 18M 7M
othertotalStockholdersEquity 12 617M 12 395M 11 974M 11 840M 11 705M 11 503M 11 607M 11 645M 11 452M
totalStockholdersEquity 4 129M 3 770M 3 332M 3 436M 3 366M 3 360M 3 537M 3 763M 3 799M 4 157M 4 383M 4 655M 6 243M 3 869M
totalEquity 4 129M 3 770M 3 332M 3 436M 3 366M 3 360M 3 537M 3 763M 3 799M 4 157M 4 383M 4 655M 6 243M 3 869M
totalLiabilitiesAndStockholdersEquity 7 633M 6 298M 5 831M 5 712M 5 668M 5 525M 5 729M 5 957M 6 726M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 633M 6 298M 5 921M 5 831M 5 712M 5 668M 5 805M 5 525M 5 729M 5 957M 6 379M 6 726M 8 646M 5 601M
totalInvestments 0 0 129M 138M 140M 189M 92M 107M 106M 294M 757M 968M 2 343M 3 318M
totalDebt 1 020M 1 026M 1 080M 1 101M 1 090M 1 063M 930M 580M 678M 545M 891M 711M 695M 562M
netDebt -3 017M -1 730M -1 548M -1 600M -1 503M -1 699M -2 242M -2 488M -2 733M -2 993M -2 978M -3 487M -3 681M -820M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2025-01-08 2022-12-31 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 676M 358M 173M 483M 60M
otherReceivables 33M 38M 0 17M 13M
prepaids 135M 88M 83M 139M 58M
totalPayables 488M 387M 295M 262M 232M
otherPayables 83M 72M 0 94M 0
accruedExpenses 499M 589M 480M 534M 390M
capitalLeaseObligationsCurrent 18M 22M 24M 22M 14M
capitalLeaseObligationsNonCurrent 44M 22M 35M 43M 29M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 12 088M 11 599M 11 541M 11 191M 7 415M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE BGNE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-09-30 2024-08-07 2024-05-08 2023-11-09 2023-08-02 2023-05-04 2022-11-09
acceptedDate 2025-11-06 06:07:16 2025-08-06 06:05:46 2025-02-27 06:12:34 2024-09-30 00:00:00 2024-08-07 06:07:59 2024-05-08 06:09:45 2025-01-08 06:02:32 2023-11-09 16:14:07 2023-08-02 06:23:42 2023-05-04 07:17:19 2022-12-30 19:00:00 2022-11-09 07:12:00 2021-12-30 19:00:00 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 125M 94M -645M -121M -120M -251M -882M 215M -381M -348M -2 004M -553M -1 413M -1 601M
depreciationAndAmortization 37M 36M 172M 71M 25M 25M 88M 22M 22M 20M 66M 16M 46M 32M
deferredIncomeTax 0 0 26M 0 0 0 689 000 750 000 -51 000 36 000 2M -7M -41M -28M
stockBasedCompensation 141M 151M 442M 115M 131M 89M 368M 96M 103M 75M 303M 78M 241M 183M
changeInWorkingCapital 0 0 -157M 130M -113M -155M -371M -58M -35M -294M 132M -86M -118M 151M
accountsReceivables -94M -42M -329M -30M -94M -80M -188M -12M 5M -136M 304M -23M -423M 10M
inventory -29M 2M -91M 24M 1M -37M -141M 1M -41M -13M -57M -44M -153M -59M
accountsPayables 28M -4M 121M 11M -44M 46M 21M 64M -10M -23M -4M 35M 20M 96M
otherWorkingCapital 0 0 142M 125M 23M -84M -63M -112M 11M -122M -111M -54M 438M 103M
otherNonCashItems 100M -17M 22M -7M -17M 194M -361M -354M -3M -17M 3M -11M -13M -21M
netCashProvidedByOperatingActivities 403M 264M -141M 188M -96M -309M -1 157M -78M -294M -564M -1 497M -562M -1 299M -1 283M
investmentsInPropertyPlantAndEquipment -48M -44M -493M -134M -110M -161M -562M -182M -121M -126M -469M -129M -315M -229M
acquisitionsNet 0 0 0 0 0 0 0 24M 0 0 -1 403M 0 52M 110M
purchasesOfInvestments 0 0 -19M 0 0 0 -17M -4M -11M -1M -17M -3M -2 191M -5 690M
salesMaturitiesOfInvestments 0 0 3M 0 0 3M 673M 19 000 191M 377M 1 564M 301M 3 147M 2 751M
otherInvestingActivites -1M -23M -227 000 -1M -51M -24M 9M -9M -20M
netCashUsedForInvestingActivites -49M -67M -134M -111M -210M -186M 68M 241M 169M
debtRepayment 0 0 -4M 14M -148M -101M -15M -51M -30M
commonStockIssued 0 0 0 6M 15M 17M 4M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 961M 35M 16M 9M 162M 7M 178M 32M 150M
netCashUsedProvidedByFinancingActivities 961M 35M 13M 23M 162M -77M 166M -20M 120M
effectOfForexChangesOnCash 0 0 -52M 28M -6M -22M -8M 525 000 -62M 11M -69M -63M 14M 18M
netChangeInCash 1 324M 255M -547M 95M -190M -421M -689M -341M -122M -331M -508M -335M 2 993M 769M
cashAtEndOfPeriod 4 111M 2 786M 2 639M 2 713M 2 618M 2 762M 3 186M 3 081M 3 422M 3 544M 3 875M 4 201M 4 383M 1 390M
cashAtBeginningOfPeriod 2 786M 2 531M 3 186M 2 618M 2 807M 3 183M 3 875M 3 422M 3 544M 3 875M 4 383M 4 535M 1 390M 621M
operatingCashFlow 403M 264M -141M 188M -96M -309M -1 157M -78M -294M -564M -1 497M -562M -1 299M -1 283M
capitalExpenditure -48M -44M -529M -134M -110M -161M -596M -182M -121M -126M -469M -129M -315M -229M
freeCashFlow 354M 220M -670M 55M -206M -470M -1 754M -260M -415M -689M -1 966M -691M -1 614M -1 512M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2025-01-08 2022-12-31 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -39M -15M 1 403M -52M -110M
netCashProvidedByInvestingActivities -548M 60M 1 077M 641M -3 168M
netDebtIssuance 145M 361M -66M 102M 290M
longTermNetDebtIssuance -19M 9M 37M 17M -22M
shortTermNetDebtIssuance 164M 352M -103M 85M 311M
netStockIssuance 0 0 0 3 443M 4 232M
netCommonStockIssuance 0 0 0 3 443M 4 232M
commonStockIssuance 0 0 0 3 443M 4 232M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 48M 56M 47M 93M 681M
netCashProvidedByFinancingActivities 193M 416M -19M 3 637M 5 203M
incomeTaxesPaid 69M 56M 30M 16M 11M
interestPaid 51M 20M 25M 30M 44M

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)

Press-releases

Show financial reports only

2024-11-12 11:00 ET
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
2024-11-06 11:01 ET
BeiGene to Present at the Jefferies London Healthcare Conference
2024-11-05 14:05 ET
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
2024-10-28 10:00 ET
BeiGene Mourns Death of Beloved Board Member Donald Glazer
2024-10-21 10:00 ET
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
2024-10-16 10:00 ET
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
2024-09-26 22:21 ET
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
2024-09-26 10:00 ET
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
2024-09-17 11:00 ET
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
2024-09-09 11:00 ET
BeiGene Announces Updates to Commercial Leadership Team
2024-09-09 05:00 ET
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
2024-08-28 10:01 ET
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-26 10:00 ET
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
2024-08-07 10:00 ET
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
2024-07-23 11:00 ET
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
2024-07-18 10:30 ET
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
2024-06-14 10:00 ET
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
2024-06-13 23:41 ET
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
2024-06-04 10:01 ET
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-28 12:00 ET
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
2024-05-24 10:00 ET
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
2024-05-14 20:01 ET
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
2024-05-08 10:00 ET
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
2024-04-26 14:34 ET
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
2024-04-24 20:01 ET
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
2024-04-23 10:00 ET
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-03-14 20:28 ET
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
2024-03-13 12:00 ET
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
2024-03-07 22:19 ET
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
2024-03-06 11:00 ET
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
2024-02-29 15:00 ET
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
2024-02-28 13:05 ET
BeiGene to Present at Upcoming Investor Conferences
2024-02-27 11:00 ET
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
2024-02-26 11:00 ET
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-26 10:00 ET
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-01-23 11:00 ET
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
2023-12-22 11:00 ET
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
2023-12-21 11:01 ET
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-29 21:01 ET
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
2023-11-28 11:00 ET
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
2023-11-21 11:00 ET
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
2023-11-17 11:00 ET
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
2023-11-09 21:01 ET
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
2023-11-08 11:00 ET
BeiGene to Present at the Jefferies London Healthcare Conference
2023-10-20 10:00 ET
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
2023-10-17 20:01 ET
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
2023-10-17 20:01 ET
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2023-10-16 10:00 ET
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
2023-10-13 15:51 ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
2023-09-19 10:15 ET
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
2023-09-19 10:00 ET
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
2023-08-31 11:00 ET
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-02 10:00 ET
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
2023-07-21 11:50 ET
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
2023-07-12 11:00 ET
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
2023-07-10 11:00 ET
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
2023-07-07 11:00 ET
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
2023-06-15 12:37 ET
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
2023-06-15 07:00 ET
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
2023-06-09 07:01 ET
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
2023-05-30 11:00 ET
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
2023-05-25 21:05 ET
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
2023-05-24 11:00 ET
BeiGene to Present at Upcoming Investor Conferences
2023-05-17 11:00 ET
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
2023-05-06 12:00 ET
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
2023-05-04 11:00 ET
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
2023-04-26 14:27 ET
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
2023-04-25 11:00 ET
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
2023-04-20 11:00 ET
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2023-04-17 18:32 ET
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
2023-04-17 18:32 ET
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
2023-04-17 18:30 ET
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
2023-04-17 18:30 ET
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
2023-04-13 11:00 ET
BeiGene Expands Presence in Latin America With Opening of Brazil Office
2023-03-30 11:00 ET
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
2023-03-21 11:00 ET
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
2023-02-27 12:00 ET
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-24 12:00 ET
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
2023-02-24 12:00 ET
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
2023-02-03 12:00 ET
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
2023-02-01 12:00 ET
BeiGene to Present at Upcoming Investor Conferences
2023-01-19 22:03 ET
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
2023-01-19 12:00 ET
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
2023-01-18 13:27 ET
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
2023-01-17 22:00 ET
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
2023-01-04 12:07 ET
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
2022-12-30 14:00 ET
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
2022-12-13 15:00 ET
 BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
2022-12-09 12:00 ET
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
2022-12-08 19:10 ET
Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab
2022-11-22 13:30 ET
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
2022-11-17 12:00 ET
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
2022-11-15 12:00 ET
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
2022-11-10 12:00 ET
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
2022-11-09 12:00 ET
BeiGene Reports Third Quarter 2022 Financial Results
2022-11-04 11:00 ET
BeiGene to Present at Upcoming Investor Conferences
2022-11-03 13:00 ET
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
2022-11-02 11:00 ET
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
2022-10-26 11:00 ET
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
2022-10-14 10:30 ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
2022-10-12 11:00 ET
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
2022-09-19 23:01 ET
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
2022-09-19 11:00 ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
2022-09-10 06:30 ET
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
2022-09-07 23:27 ET
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-23 11:00 ET
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
2022-08-15 11:00 ET
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
2022-08-09 10:00 ET
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
2022-08-04 11:00 ET
BeiGene Reports Second Quarter 2022 Financial Results
2022-07-14 10:00 ET
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
2022-07-13 13:00 ET
BeiGene Appoints Chan Lee as General Counsel
2022-07-12 11:00 ET
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
2022-07-06 11:00 ET
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
2022-06-30 08:00 ET
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
2022-06-21 11:00 ET
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
2022-06-13 11:30 ET
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
2022-06-13 11:00 ET
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
2022-06-10 11:00 ET
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
2022-06-10 11:00 ET
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
2022-06-08 12:00 ET
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-05-26 21:00 ET
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
2022-05-17 05:00 ET
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
2022-05-12 14:00 ET
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
2022-05-05 11:00 ET
BeiGene Reports First Quarter 2022 Financial Results
2022-05-04 09:53 ET
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
2022-04-29 11:00 ET
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
2022-04-28 11:00 ET
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
2022-04-27 14:00 ET
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
2022-04-27 10:00 ET
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
2022-04-26 11:00 ET
BeiGene Introduces Global Environmental, Social, and Governance Strategy
2022-04-25 20:09 ET
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
2022-04-21 11:00 ET
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
2022-04-19 10:00 ET
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
2022-04-15 10:00 ET
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
2022-04-11 10:00 ET
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
2022-04-08 11:00 ET
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
2022-04-06 09:00 ET
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
2022-04-05 12:00 ET
858 Therapeutics Expands Board of Directors and Leadership Team
2022-03-15 12:00 ET
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
2022-03-11 12:00 ET
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
2022-03-03 12:00 ET
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
2022-03-01 10:30 ET
BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference
2022-02-25 12:00 ET
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-22 12:00 ET
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
2022-02-22 12:00 ET
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
2022-02-17 10:00 ET
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
2022-02-08 11:00 ET
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
2022-02-01 12:00 ET
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
2022-01-28 10:00 ET
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
2022-01-24 10:00 ET
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
2022-01-20 10:00 ET
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
2022-01-06 12:30 ET
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
2022-01-06 08:30 ET
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2021-12-20 11:15 ET
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
2021-12-20 09:00 ET
BeiGene Announces Launch of Bioisland Innovation Center
2021-12-15 09:00 ET
BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom’s MHRA for the Treatment of Adults with Waldenström’s Macroglobulinemia in Great Britain
2021-12-15 04:00 ET
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
2021-12-14 04:00 ET
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
2021-12-12 14:30 ET
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
2021-12-11 14:30 ET
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
2021-12-10 08:00 ET
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
2021-12-03 04:00 ET
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
2021-12-03 04:00 ET
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
2021-12-03 04:00 ET
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib
2021-12-02 08:00 ET
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
2021-11-30 14:00 ET
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
2021-11-23 22:00 ET
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
2021-11-23 13:15 ET
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
2021-11-23 12:00 ET
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
2021-11-22 12:00 ET
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
2021-11-15 00:00 ET
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
2021-11-04 20:05 ET
BeiGene Reports Third Quarter 2021 Financial Results
2021-11-04 13:00 ET
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
2021-10-20 11:00 ET
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
2021-10-10 21:00 ET
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
2021-10-07 20:05 ET
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
2021-09-20 11:00 ET
BeiGene Announces Inclusion in FTSE Russell Indices
2021-09-17 12:00 ET
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
2021-09-15 11:00 ET
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
2021-09-13 04:00 ET
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
2021-09-12 22:05 ET
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
2021-09-01 21:33 ET
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
2021-08-22 23:00 ET
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
2021-08-18 05:00 ET
BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Waldenström’s Macroglobulinaemia
2021-08-17 13:23 ET
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma
2021-08-17 11:00 ET
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
2021-08-16 11:00 ET
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021
2021-08-05 20:05 ET
BeiGene Reports Second Quarter 2021 Financial Results
2021-08-03 11:00 ET
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
2021-07-30 00:00 ET
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
2021-07-26 11:00 ET
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
2021-07-09 04:00 ET
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
2021-07-08 00:00 ET
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
2021-07-07 11:00 ET
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
2021-06-23 04:00 ET
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
2021-06-18 20:30 ET
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
2021-06-17 11:00 ET
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
2021-06-11 07:00 ET
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
2021-06-11 07:00 ET
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
2021-06-09 11:00 ET
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
2021-06-07 21:00 ET
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
2021-06-04 13:00 ET
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
2021-06-04 13:00 ET
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
2021-06-03 10:30 ET
Zhongchao Inc. Announces the On-Going One-Year Leukemia Education Project with Bethune Foundation and BeiGene Shanghai
2021-06-01 14:00 ET
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
2021-05-21 11:00 ET
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
2021-05-19 21:00 ET
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
2021-05-19 11:00 ET
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
2021-05-12 14:00 ET
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
2021-05-07 04:00 ET
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
2021-05-06 20:05 ET
BeiGene Reports First Quarter 2021 Financial Results
2021-04-28 11:00 ET
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
2021-04-12 17:30 ET
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
2021-04-11 20:00 ET
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
2021-04-08 11:00 ET
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
2021-04-08 11:00 ET
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
2021-04-07 23:00 ET
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
2021-03-30 12:30 ET
BeiGene Announces New Chief Financial Officer, Julia Wang
2021-03-17 10:50 ET
111, Inc. Enters into First-Ever Strategic Partnership with BeiGene
2021-03-10 21:30 ET
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
2021-03-10 12:00 ET
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
2021-03-05 13:30 ET
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer
2021-03-02 12:00 ET
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
2021-02-26 12:00 ET
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
2021-02-25 21:05 ET
BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-17 22:00 ET
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
2021-02-17 12:00 ET
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
2021-01-27 22:45 ET
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
2021-01-25 12:00 ET
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
2021-01-14 04:00 ET
China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer
2021-01-11 21:30 ET
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
2021-01-11 12:00 ET
Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology
2021-01-07 12:00 ET
BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference
2020-12-28 04:00 ET
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)
2020-12-08 00:00 ET
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
2020-12-07 15:00 ET
BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenström’s Macroglobulinemia at the 62nd ASH Annual Meeting
2020-12-06 17:30 ET
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting
2020-12-02 04:00 ET
BeiGene Announces Pricing of Public Offering by Selling Shareholders
2020-12-01 21:15 ET
BeiGene Launches Proposed Public Offering by Selling Shareholders
2020-11-23 12:00 ET
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-20 01:00 ET
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
2020-11-17 12:00 ET
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
2020-11-09 12:04 ET
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China
2020-11-05 21:05 ET
BeiGene Reports Third Quarter 2020 Financial Results
2020-11-05 14:00 ET
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting
2020-10-06 11:00 ET
BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071
2020-09-21 11:00 ET
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
2020-09-17 22:05 ET
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
2020-09-10 13:00 ET
BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-09 11:00 ET
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia
2020-09-04 13:15 ET
BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
2020-08-27 11:00 ET
BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals
2020-08-25 11:00 ET
BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors
2020-08-24 12:08 ET
Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China
2020-08-06 20:05 ET
BeiGene Reports Second Quarter 2020 Financial Results
2020-08-05 11:00 ET
BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
2020-07-27 13:15 ET
Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
2020-07-20 10:30 ET
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
2020-07-17 13:00 ET
BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
2020-07-15 21:00 ET
BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
2020-07-13 00:00 ET
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
2020-07-02 11:00 ET
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
2020-07-01 22:00 ET
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
2020-01-03 13:53 ET
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
2019-11-05 13:00 ET
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate
2019-10-08 19:54 ET
Lifshitz & Miller LLP Announces Investigation of Aflac Inc., BeiGene, Ltd., Meredith Corporation, New Relic, Inc., Ollie's Bargain Outlet Holdings, Inc., SmileDirectClub, Inc., and Sonim Technologies, Inc.
2019-09-13 00:03 ET
SHAREHOLDER ALERT: Hagens Berman Notifies Investors in BeiGene, Ltd. (BGNE) of Securities Fraud Investigation
2019-03-06 12:00 ET
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
2019-03-04 12:00 ET
BeiGene to Present at Upcoming Investor Conferences
2019-02-27 21:15 ET
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

SEC forms

Show financial reports only

SEC form 8
2026-04-14 13:49 ET
BeiGene published news for 2026 q1
SEC form 8
2026-04-14 13:49 ET
BeiGene published news for 2026 q1
SEC form 10
2026-02-26 06:09 ET
BeiGene published news for 2025 q4
SEC form 8
2026-02-26 06:04 ET
BeiGene published news for 2025 q4
SEC form 8
2026-02-26 06:04 ET
BeiGene published news for 2025 q4
SEC form 10
2025-11-06 06:07 ET
BeiGene reported for 2025 q3
SEC form 8
2025-11-06 06:03 ET
BeiGene published news for 2025 q3
SEC form 8
2025-11-06 06:03 ET
BeiGene reported for 2025 q3
SEC form 8
2025-08-29 06:52 ET
BeiGene published news for 2025 q2
SEC form 8
2025-08-29 06:52 ET
BeiGene published news for 2025 q2
SEC form 10
2025-08-06 10:05 ET
BeiGene reported for 2025 q2
SEC form 8
2025-08-06 10:02 ET
BeiGene published news for 2025 q2
SEC form 8
2025-08-06 10:02 ET
BeiGene reported for 2025 q2
SEC form 10
2025-05-07 10:09 ET
BeiGene published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
BeiGene reported for 2025 q1
SEC form 8
2025-05-07 00:00 ET
BeiGene published news for 2025 q1
SEC form 8
2025-05-07 00:00 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-29 21:03 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-28 20:09 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-28 00:00 ET
BeiGene published news for 2025 q1
SEC form 8
2025-04-28 00:00 ET
BeiGene published news for 2025 q1
SEC form 10
2025-02-27 11:12 ET
BeiGene published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
BeiGene reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
BeiGene published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
BeiGene published news for 2024 q4
SEC form 10
2024-11-12 06:06 ET
BeiGene reported for 2024 q3
SEC form 8
2024-11-12 06:03 ET
BeiGene published news for 2024 q3
SEC form 8
2024-11-12 06:03 ET
BeiGene published news for 2024 q3
SEC form 10
2024-11-12 00:00 ET
BeiGene published news for 2024 q3
SEC form 8
2024-08-29 00:00 ET
BeiGene published news for 2024 q2
SEC form 8
2024-08-29 00:00 ET
BeiGene published news for 2024 q2
SEC form 10
2024-08-07 06:07 ET
BeiGene published news for 2024 q2
SEC form 8
2024-08-07 00:00 ET
BeiGene published news for 2024 q2
SEC form 8
2024-08-07 00:00 ET
BeiGene published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
BeiGene reported for 2024 q2
SEC form 10
2024-05-08 06:09 ET
BeiGene reported for 2024 q1
SEC form 8
2024-05-08 06:06 ET
BeiGene published news for 2024 q1
SEC form 8
2024-05-08 06:06 ET
BeiGene published news for 2024 q1
SEC form 10
2024-05-08 00:00 ET
BeiGene published news for 2024 q1
SEC form 8
2024-04-26 00:00 ET
BeiGene published news for 2024 q1
SEC form 8
2024-04-26 00:00 ET
BeiGene published news for 2024 q1
SEC form 10
2024-02-26 06:16 ET
BeiGene published news for 2023 q4
SEC form 8
2024-02-26 06:02 ET
BeiGene published news for 2023 q4
SEC form 8
2024-02-26 06:02 ET
BeiGene reported for 2023 q4
SEC form 10
2024-02-26 00:00 ET
BeiGene published news for 2023 q4
SEC form 10
2023-11-09 16:14 ET
BeiGene reported for 2023 q3
SEC form 8
2023-11-09 16:08 ET
BeiGene published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
BeiGene published news for 2023 q3
SEC form 8
2023-08-29 00:00 ET
BeiGene published news for 2023 q2
SEC form 10
2023-08-02 06:23 ET
BeiGene reported for 2023 q2
SEC form 6
2023-08-02 06:13 ET
BeiGene published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
BeiGene published news for 2023 q2
SEC form 6
2023-07-24 16:13 ET
BeiGene published news for 2023 q2
SEC form 6
2023-07-11 06:01 ET
BeiGene published news for 2023 q2
SEC form 6
2023-06-20 18:59 ET
BeiGene published news for 2023 q1
SEC form 6
2023-06-20 18:37 ET
BeiGene published news for 2023 q1
SEC form 6
2023-06-15 16:43 ET
BeiGene published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
BeiGene published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
BeiGene published news for 2023 q1
SEC form 8
2023-04-25 00:00 ET
BeiGene published news for 2023 q1
SEC form 10
2023-02-27 00:00 ET
BeiGene reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
BeiGene reported for 2022 q4
SEC form 10
2022-11-09 00:00 ET
BeiGene reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
BeiGene reported for 2022 q3
SEC form 8
2022-08-30 00:00 ET
BeiGene published news for 2022 q2
SEC form 10
2022-08-08 00:00 ET
BeiGene reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
BeiGene reported for 2022 q2
SEC form 10
2022-05-09 00:00 ET
BeiGene reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
BeiGene reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
BeiGene published news for 2022 q1
SEC form 10
2022-02-28 00:00 ET
BeiGene published news for 2021 q4
SEC form 8
2022-02-25 00:00 ET
BeiGene published news for 2021 q4
SEC form 8
2021-11-16 00:00 ET
BeiGene published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
BeiGene published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
BeiGene published news for 2021 q3
SEC form 8
2021-08-05 00:00 ET
BeiGene published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
BeiGene published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
BeiGene published news for 2021 q2
SEC form 8
2021-06-30 00:00 ET
BeiGene published news for 2021 q1
SEC form 8
2021-05-14 00:00 ET
BeiGene published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
BeiGene published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
BeiGene published news for 2021 q1